Copies of the proposed forms and a description of the collection methods are available upon request to the Director, Bureau of the Census, Washington, D.C. 20233.

Any suggestions or recommendations concerning the subject matter of the proposed survey submitted in writing to the Director of the Bureau of the Census on or before December 9, 1974.

VINCENT P. BARABBA,
Director,
Bureau of the Census.

[FR Doc.74-26232 Filed 11-7-74;8:45 am]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration

[Docket No. FDC-D-135, etc.; NDA 1-650, etc.]

OVER-THE-COUNTER ANTACID DRUG PRODUCTS

Withdrawal of Approval of New Drug Applications

A notice of opportunity for hearing was published in the FEDERAL REGISTER of June 4, 1974 (39 FR 19882), in which the Commissioner of Food and Drugs proposed to issue an order under section 505 (e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) withdrawing approval of the new drug applications and all amendments and supplements thereto for certain over-the-counter (OTC) antacid drug products and determining the new drug status of such products. The basis of the proposed action was: (1) the lack of substantial evidence that the drug products will have the effect they purport or are represented to have under the conditions of use prescribed, recommended, or suggested in the labeling, other than those permitted by the final order on OTC antacid drug products published in the same issue of the FEDERAL REGISTER (39 FR 19862); and (2) such drug products are not shown to be safe for use except under the conditions of use required for safety reasons, and are not shown to be safe for use under the conditions of use excluded for safety reasons, by the final order on OTC antacid drug products; and (3) the labeling of the drug products, to the extent it differs from the applicable labeling requirements of the final order on OTC antacid drug products, based on a fair evaluation of all material facts, is false and misleading.

By letter of June 5, 1974, Cole Pharmacal Company, Inc., informed the Food and Drug Administration that Kamat tablets (NDA 1-952) were discontinued in 1967 and that they did not wish to avail themselves of the opportunity for hearing. No other holder of an affected application or other interested person filed a written appearance of election as provided by said notice. The failure to file such an appearance as required by 21 CFR 314.200 constitutes an election by such persons not to avail themselves of the opportunity for hearing and a waiver of any contentions concerning the legal status of any such drug product, including identical, related, or similar drug products as defined in 21 CFR 310.6.

All identical, related, or similar products, not the subject of an approved new drug application, are subject to this notice (21 CFR 310.6). Any person who wishes to determine whether a specific product is subject to this notice should write to the Food and Drug Administration, Bureau of Drugs, Office of Compliance (HFD-300), 5600 Fishers Lane, Rockville, MD 20852.

The Commissioner, pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505, 52 Stat. 1052-1053, as amended; 21 U.S.C. 355), and under the authority delegated to him (21 CFR 2.120), finds that, on the basis of new information before him with respect to the drug products, evaluated together with the evidence available to him at the time of approval of the applications, (1) there is a lack of substantial evidence that the drug products will have the effect they purport or are represented to have for any condition of use prescribed, recommended, or suggested in the labeling, other than those permitted by the final order on OTC antacid drug products; and (2) such drug products are not shown to be safe for use except under the conditions of use required for safety reasons, and are not shown to be safe for use except under the conditions of use excluded for safety reasons, by the final order on OTC antacid drug products; and (3) the labeling of the drug products, to the extent it differs from the applicable labeling requirements of the final order on OTC antacid drug products, based on a fair evaluation of all material facts, is false and misleading.

Therefore, pursuant to the foregoing finding, approval of the following new drug applications and all amendments and supplements thereto is withdrawn effective November 18, 1974:

NDA No.	Drug	Firm
1-650	Citralka liquid	Parke, Davis & Co., Detroit, Mich. 48232.
1-875	Chooz Chewing Gum	Pharmaco, Inc., Kenilworth, N.J. 07033.
1-952	Kamat tablets	Cole Pharmacal Co., Inc., St. Louis, Mo. 63178.
2-436	Amphojel tablets	Wyeth Laboratories, division of American Home Products Corp., Philadelphia, Pa. 19101.
2-545	Gelusil liquid	Warner-Chilcott Laboratories, division of Warner-Lambert Co., Morris Plains, N.J. 07950.
3-304	Bismakaolin suspension	Vale Chemical Co., Inc., Allentown, Pa. 18102.
3-807	Magsal suspension	Endo Laboratories, Inc., Garden City, Long Island, N.Y. 11530.
4-380	Gelusil tablets	Warner-Chilcott Laboratories, division of Warner-Lambert Co., Morris Plains, N.J. 07950.
5-668	Alglyn tablets, Alglyn magma, Belglyn tablets.	Brayton Pharmaceutical Co., Chattanooga, Tenn. 37409.
6-547	Alzinox tablets	Smith, Miller & Patch, New Brunswick, N.J. 08902.
6-738	Carmethose suspension, Carmethose magnesium oxide tablets, Carmethose-Trasentine.	Ciba Pharmaceutical Co., division of Ciba-Geigy Corp., Summit, N.J. 07901.
7-706	Resinat capsules, Resinat tablets	Merrell-National Laboratories, division of Richardson-Merrell, Inc., Cincinnati, Ohio 45215.
7-911	Kolantyl tablets	Do.
8-431	Dimacid B tablets	Otis Chapp & Son, Inc., Cambridge, Mass. 02139.
8-467	Kolantyl Gel	Merrell-National Laboratories, division of Richardson-Merrell, Inc., Cincinnati, Ohio 45215.
9-100	Rolaids Antacid Mint tablets	American Chicle Co., division of Warner-Lambert Co., Morris Plains, N.J. 07950.
9-329	Duplexin tablets	Whitehall Laboratories, division of American Home Products Corp., New York, N.Y. 10017.
12-165	Rolaids Antacid Mint with HMAS	American Chicle Co., division of Warner-Lambert Co., Morris Plains, N.J. 07950.
12-298	"A"Plus tablets	Vick Chemical Co., division of Richardson-Merrell, Inc., New York, N.Y. 10017.
15-183	Equilet Antacid tablets	Mission Pharmacal Co., San Antonio, Tex. 78296.

This notice also represents a determination of the legal status of the above products as well as all identical, similar, or related products not the subject of an approved new drug application (21 CFR 310.6) including those OTC antacid products for which approval has previously been withdrawn on the ground of failure to file reports required pursuant to section 505(j) of the act and which appeared in the FEDERAL REGISTER as follows:

a. Docket FDA-D-135 published in the FEDERAL REGISTER of July 24, 1970 (35 FR 11929).

b. Docket FDC-D-259 published in the FEDERAL REGISTER of April 6, 1971 (36 FR 6529).

c. Docket FDC-D-269 (Docket number originally published incorrectly as FDC-D-259; correction published in the FEDERAL REGISTER of November 24, 1971 (36 FR 22324) to read FDC-D-269) published in the FEDERAL REGISTER of August 6, 1971 (36 FR 14493) and republished in the FEDERAL REGISTER of September 23, 1971 (36 FR 18885).

d. Docket FDC-D-445 published in the FEDERAL REGISTER of March 18, 1972 (37 FR 5711).

e. Docket FDC-D-393 published in the FEDERAL REGISTER of March 28, 1972 (37 FR 6342).

f. Docket FDC-D-492 published in the FEDERAL REGISTER of August 8, 1972 (37 FR 15948).

Any such drug products may not lawfully be marketed except in compliance with 21 CFR Part 331 or the interim re-

quirements for Category III drug products specified in the final order on OTC antacid drug products published in the FEDERAL REGISTER of June 4, 1974 (39 FR 19862).

The Food and Drug Administration will initiate appropriate regulatory action to remove such noncomplying drug products from the market promptly after the applicable effective date established in the final order on OTC antacid drug products.

Dated: October 31, 1974.

SAM D. FINE,
Associate Commissioner for Compliance.

[FR Doc.74-26045 Filed 11-7-74;8:45 am]

Health Services Administration

INTERAGENCY COMMITTEE ON EMERGENCY MEDICAL SERVICES

Notice of Meeting

Pursuant to the Federal Advisory Act (Pub. L. 92-463), the Administrator, Health Services Administration, announces the meeting dates and other required information for the following National Advisory body scheduled to assemble during the month of December 1974:

Committee name	Date, time, place	Type of meeting and/or contact person
Interagency Committee on Emergency Medical Services.	December 5, 9 a.m. to 4 p.m., Snow Room (5051), DHEW North Bldg., 330 Independence Ave. SW., Washington, D.C.	Open—Contact John Reardon, Room 320, DEMS/BMS, 6525 Belcrest Rd., West Hyattsville, Md. (301) 436-6284.

Purpose. The Committee will provide for the communication and exchange of information necessary to maintain the coordination and effectiveness among such Federal programs and activities and make recommendations to the Secretary respecting the administration of grants and contracts under Title XII, including making regulations for the emergency medical services systems program.

Agenda. The agenda will include a review of the Committee Charter, a review of current DHEW/EMS program activities and an outline of planned activites for 1975-76. The Committee will discuss interagency EMS activities for system implementation and set the Committee meeting dates for 1975.

Agenda items are subject to change as priorities dictate.

The meeting is open to the public for observation. Anyone wishing to attend, obtain a roster of the members, or other relevant information should contact the person listed above. Public seating is limited to forty. Please contact at least 24/hours before the meeting.

Date: November 4, 1974.

ANDREW J. CARDINAL,
Associate Administrator for Management, Health Services Administration.

[FR Doc.74-26184 Filed 11-7-74;8:45 am]

National Institutes of Health

BOARD OF SCIENTIFIC COUNSELORS

Amended Notice of Meeting

Notice is hereby given of a change in the meeting time of the Board of Scientific Counselors, National Eye Institute, which was published in the FEDERAL REGISTER on October 23, 1974, 39 FR 37662.

This Board was to have convened at 1 p.m. on December 2 and 9 a.m. on December 3, but has been changed to 8:30 a.m. to 5 p.m. on December 2, and 8:30 a.m. to adjournment on December 3, in Building 31, room 6A21, at the National Institutes of Health, Bethesda, Maryland.

The meeting will be open to the public from 8:30 a.m. to 9:30 a.m. on December 2, 1974 for general remarks by the Institute Director on matters concerning the intramural program of the Laboratory of Vision Research, a budget discussion, and legislative developments. Attendance by the public will be limited to space available.

SUZANNE L. FREMEAU,
Committee Management Officer, National Institutes of Health.

NOVEMBER 5, 1974.

[FR Doc.74-26309 Filed 11-7-74;8:45 am]

NATIONAL CANCER ADVISORY BOARD

Amended Notice of Meeting

Notice is hereby given of an additional agenda item in the meeting November 18-20, 1974 of the National Cancer Advisory Board, National Cancer Institute, National Institutes of Health, Building 31, Conference Room 6, which was published in the FEDERAL REGISTER October 17, 1974, Vol. 39, No. 202, Page 37086. The Board will hear a report from its Subcommittee concerned with the identification and organization of available scientific information, as requested by the President, in support of a previous Board recommendation calling for regulation of high tar and nicotine cigarettes.

The report will be presented on the morning of November 18, 1974 during an open session of the meeting. Attendance by the public will be limited to space available.

SUZANNE L. FREMEAU,
Committee Management Officer, National Institutes of Health.

NOVEMBER 5, 1974.

[FR Doc.74-26308 Filed 11-7-74;8:45 am]

DEPARTMENT OF TRANSPORTATION

Federal Railroad Administration

[FRA Waiver Petition Docket No. RSFC-74-14]

APALACHICOLA NORTHERN RAILROAD CO.

Waiver of Freight Car Safety Standards

The Apalachicola Northern Railroad Company (AN) has petitioned the Federal Railroad Administration (FRA) for exemption from § 215.223 of the FRA Freight Car Safety Standards in order to continue operating 4 flat cars. These cars are used in the area of Port St. Joe Florida. They are equipped with cast iron wheels which are prohibited, effective January 1, 1975, under FRA regulations (49 CFR 215.223).

The cars, which were built in 1914, carry Apalachicola Northern reporting marks and bear AN identification numbers 1607, 1613, 1614, and 1619. The cars, in addition to being equipped with prohibited wheels, are outfitted with Farlow draft gear whose use is restricted under FRA regulations (49 CFR 215.225). They are not used in interchange and their maximum operating speed is 25 miles per hour. Petitioner seeks a permanent exemption for the prohibited components and permanent approval to continue operating with the restricted components.

Interested persons are invited to participate in these proceedings by submitting written data, views, or comments. FRA does not anticipate scheduling an opportunity for oral comment on these petitions since the facts do not appear to warrant it. An opportunity to present oral comments will be provided however, if requested by any interested person prior to November 25, 1974. All communications concerning these petitions should identify the appropriate Docket Number (FRA Waiver Petition Docket Number RSFC-74-14) and should be submitted in triplicate to the Docket Clerk, Office of Chief Counsel, Federal Railroad Administration, Nassif Building, 400 Seventh Street, SW, Washington, D.C. 20590. Communications received before December 10, 1974 will be considered by the Federal Railroad Administration before final action is taken. Comments received after that date will be considered so far as practicable. All comments received will be available, both before and after the closing date for communications, for examination by interested persons during regular business hours in Room 5101, Nassif Building, 400 Seventh Street, SW, Washington, D.C. 20590.

This notice is issued under the authority of section 202, 84 Stat. 971, U.S.C. 431; and § 1.49(n) of the regulations of the Office of the Secretary of Transportation, 49 CFR 1.49(n).

Issued in Washington, D.C. on November 5, 1974.

DONALD W. BENNETT,
Chief Counsel.

[FR Doc.74-26246 Filed 11-7-74;8:45 am]

[FRA Waiver Petition Docket No. RSFC-74-12]

BURLINGTON NORTHERN

Waiver of Freight Car Safety Standards

The Burlington Northern (BN) has petitioned the Federal Railroad Administration (FRA) for exemption from § 215.223 of the FRA Freight Car Safety Standards in order to continue operating 400 log cars. These cars are used for lumber service in the States of Washington and Oregon. They are equipped with cast iron wheels which are prohibited, effective January 1, 1975, under FRA Regulations (49 CFR 215.223).